Bauer takes role of president at Chemwerth

Formerly with Sandoz

Jeffrey Bauer has taken over as president of ChemWerth, a US supplier of active pharmaceutical ingredients for generic medicines.

Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.

Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.

ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like

Regulatory
Measurement uncertainty explained – Why it matters more than you think

Measurement uncertainty explained – Why it matters more than you think

In regulated environments, where decisions often depend on whether a result passes or fails a defined limit, understanding measurement uncertainty becomes critical
Manufacturing
ACI expands HPLC portfolio with premium check valves for liquid chromatography systems

ACI expands HPLC portfolio with premium check valves for liquid chromatography systems

New aftermarket check valves provide a cost-effective, high-reliability alternative for Agilent and Waters HPLC/UPLC systems
Pharmaceutical
MSD partners with Abu Dhabi to explore regional pharma logistics hub in HELM Cluster

MSD partners with Abu Dhabi to explore regional pharma logistics hub in HELM Cluster

The collaboration would strengthen supply chain resilience and accelerate access to innovative therapies across the region, subject to approvals, positioning Abu Dhabi as a secure distribution gateway for global pharma
Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Neuland Laboratories announces new $20m process development lab in Hyderabad

Neuland Laboratories announces new $20m process development lab in Hyderabad

The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Subscribe now